查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1545568

人工胰臟装置系统的全球市场

Artificial Pancreas Device Systems
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

预计到 2030 年全球人工胰臟装置系统市场将达到 15 亿美元

2023年全球人工胰臟装置系统市场估计为4.59亿美元，预计到2030年将达到15亿美元，2023-2030年分析期间复合年增长率为18.8%。阈值悬挂设备系统是本报告分析的细分市场之一，预计复合年增长率为 18.8%，到分析期结束时将达到 12 亿美元。分析期间，控制目标 (CTT) 系统产业的复合年增长率预计为 19.7%。

美国市场预计将达到1.269亿美元，中国预计复合年增长率为17.8%。

预计2023年美国人工胰臟装置系统市场规模将达1.269亿美元。中国作为世界第二大经济体，预计2023年至2030年复合年增长率为17.8%，到2030年市场规模将达到2.302亿美元。其他值得注意的区域市场包括日本和加拿大，预计在分析期间复合年增长率分别为 16.5% 和 15.8%。在欧洲，德国的复合年增长率预计约为 13.6%。

全球人工胰臟设备系统市场 - 主要趋势与驱动因素总结

人工胰臟装置系统将如何改变糖尿病治疗？

人工胰臟装置系统 (APDS) 已成为糖尿病照护领域的突破性进步，特别是对于需要精确和持续胰岛素管理的 1 型糖尿病患者。这些系统透过将连续血糖监测仪 (CGM) 与胰岛素帮浦和先进演算法整合来实现胰岛素管理流程的自动化，以密切模仿健康胰臟的功能。透过以最少的人工干预将血糖浓度维持在目标范围内，APDS 显着减轻了糖尿病管理的负担，从而改善患者的治疗结果并提高生活品质。随着技术的不断进步，与传统的胰岛素输送方法相比，这些系统提供了无与伦比的精确度和控制，被誉为糖尿病治疗的未来。

哪些技术创新正在推动人工胰臟系统的成功？

持续的技术创新，特别是感测器的准确性、演算法的复杂性和无缝设备集成，极大地推动了人工胰腺设备系统的成功。 CGM 技术的最新改进已经开发出感测器，可以透过更少的校准提供高精度和可靠的葡萄糖测量，这是 APDS 有效性的一个重要因素。先进的演算法可以预测血糖趋势并即时自动调整胰岛素分泌，使这些系统能够更好地回应身体的需求。同时管理胰岛素和升糖素的双激素系统的发展代表着在运动、疾病和其他困难情况下增强血糖控制的一个有希望的突破。这些创新不仅提高了 APDS 的有效性，而且使其在日常使用中更容易使用、更舒适。

支持人工胰臟系统推广的新趋势是什么？

许多新趋势正在推动人工胰臟设备系统的普及，反映出向更个性化和更容易获得的糖尿病护理的更广泛转变。个人化医疗的推动导致了针对个别患者独特需求的 APDS 的开发，使这些系统更有效、更易于使用。远端医疗和远端监控能力的兴起也促进了 APDS 的扩散。这些技术允许连续血糖监测和胰岛素调整，而无需亲自访问。此外，糖尿病管理设备健康保险覆盖率的扩大也让更多人更容易使用 APDS。 1 型糖尿病的盛行率不断上升，尤其是在年轻人中，进一步推动了对这些系统的需求，将其作为改善长期健康结果并儘量减少与血糖控制不良相关的风险的手段。

推动人工胰臟设备系统市场成长的因素有哪些？

人工胰臟设备系统市场的成长是由塑造糖尿病管理未来的几个关键因素所推动的。全球糖尿病（尤其是第 1 型糖尿病）盛行率不断上升，迫切需要更准确、更有效的血糖管理解决方案。连续血糖监测、胰岛素帮浦和人工智慧驱动演算法的技术进步显着提高了 APDS 的性能和可靠性，使其对患者和医疗保健提供者都具有吸引力。远端医疗服务的扩展和穿戴式健康技术的日益普及，透过提供更方便、更有效的糖尿病管理选择，进一步推动了市场的发展。此外，对儿科糖尿病治疗的日益重视正在推动更易于使用、侵入性较小的设备的开发，从而扩大了市场潜力。随着医疗保健系统继续优先考虑基于价值的护理，APDS 改善患者治疗结果和降低长期糖尿病管理成本的能力预计将进一步推动市场成长。

受访企业范例（共47家）

  • Beta Bionics, Inc.
  • Bigfoot Biomedical, Inc.
  • Johnson & Johnson
  • Medtronic PLC
  • Pancreum, Inc.
  • Tandem Diabetes Care, Inc.
  • TypeZero Technologies LLC

目录

第一章调查方法

第 2 章执行摘要

  • 市场概况
  • 主要企业
  • 市场趋势和驱动因素
  • 全球市场展望

第三章市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 其他欧洲国家
  • 亚太地区
  • 其他领域

第四章 比赛

简介目录
Product Code: MCP10385

Global Artificial Pancreas Device Systems Market to Reach US$1.5 Billion by 2030

The global market for Artificial Pancreas Device Systems estimated at US$459.0 Million in the year 2023, is expected to reach US$1.5 Billion by 2030, growing at a CAGR of 18.8% over the analysis period 2023-2030. Threshold Suspended Device Systems, one of the segments analyzed in the report, is expected to record a 18.8% CAGR and reach US$1.2 Billion by the end of the analysis period. Growth in the Control-to-Target (CTT) Systems segment is estimated at 19.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$126.9 Million While China is Forecast to Grow at 17.8% CAGR

The Artificial Pancreas Device Systems market in the U.S. is estimated at US$126.9 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$230.2 Million by the year 2030 trailing a CAGR of 17.8% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 16.5% and 15.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 13.6% CAGR.

Global Artificial Pancreas Device Systems Market - Key Trends and Drivers Summarized

How Are Artificial Pancreas Device Systems Transforming Diabetes Care?

Artificial pancreas device systems (APDS) have emerged as a groundbreaking advancement in diabetes care, particularly for those with Type 1 diabetes who require precise and continuous insulin management. These systems automate the process of insulin delivery by integrating continuous glucose monitors (CGMs) with insulin pumps and advanced algorithms, closely mimicking the function of a healthy pancreas. By maintaining glucose levels within a target range with minimal manual intervention, APDS significantly lighten the burden of diabetes management, leading to improved patient outcomes and an enhanced quality of life. As technology continues to advance, these systems are being hailed as the future of diabetes treatment, offering unmatched precision and control compared to traditional insulin administration methods.

What Technological Innovations Are Driving the Success of Artificial Pancreas Systems?

The success of artificial pancreas device systems has been largely driven by continuous technological innovations, particularly in sensor accuracy, algorithm sophistication, and seamless device integration. Recent improvements in CGM technology have resulted in sensors that provide highly accurate and reliable glucose readings with fewer calibrations, a critical component for the effectiveness of APDS. Advanced algorithms capable of predicting glucose trends and automatically adjusting insulin delivery in real-time have made these systems even more responsive to the body’s needs. The development of dual-hormone systems that administer both insulin and glucagon represents a promising leap forward, offering enhanced glucose control during exercise, illness, or other challenging conditions. These innovations have not only improved the efficacy of APDS but also made them more user-friendly and comfortable for everyday use.

What Emerging Trends Are Fueling the Adoption of Artificial Pancreas Systems?

A number of emerging trends are fueling the widespread adoption of artificial pancreas device systems, reflecting a broader shift toward more personalized and accessible diabetes care. The push for personalized medicine has led to the development of APDS tailored to the unique needs of individual patients, making these systems more effective and user-friendly. The rise of telemedicine and remote monitoring capabilities has also contributed to the growing popularity of APDS, as these technologies enable continuous glucose monitoring and insulin adjustments without the need for in-person visits. Additionally, expanded health insurance coverage for diabetes management devices is making APDS more accessible to a wider audience. The increasing prevalence of Type 1 diabetes, especially among younger populations, is further driving the demand for these systems as a means to improve long-term health outcomes and minimize the risks associated with poor glucose control.

Which Factors Are Fueling the Growth of the Artificial Pancreas Device Systems Market?

The growth in the artificial pancreas device systems market is fueled by several key factors that are shaping the future of diabetes management. The rising global prevalence of diabetes, particularly Type 1 diabetes, has created an urgent need for more precise and effective glucose management solutions. Technological advancements in continuous glucose monitoring, insulin pumps, and AI-driven algorithms have significantly improved the performance and reliability of APDS, making them more attractive to both patients and healthcare providers. The expansion of telehealth services and the increasing adoption of wearable health technologies are further boosting the market by providing more convenient and effective diabetes management options. Additionally, the growing emphasis on pediatric diabetes care is driving the development of more user-friendly and less invasive devices, broadening the market’s potential. As healthcare systems continue to prioritize value-based care, the ability of APDS to improve patient outcomes and reduce long-term diabetes management costs is expected to further propel the market’s growth.

Select Competitors (Total 47 Featured) -

  • Beta Bionics, Inc.
  • Bigfoot Biomedical, Inc.
  • Johnson & Johnson
  • Medtronic PLC
  • Pancreum, Inc.
  • Tandem Diabetes Care, Inc.
  • TypeZero Technologies LLC

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Artificial Pancreas Device Systems - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Diabetes Propels Growth in Artificial Pancreas Device Systems Market
    • Advancements in Continuous Glucose Monitoring (CGM) Drives Adoption
    • Integration of Insulin Pumps with Advanced Algorithms Expands Addressable Market Opportunity
    • Regulatory Approvals for Hybrid Closed-Loop Systems Propel Market Expansion
    • Improved Patient Outcomes with Automated Insulin Delivery Systems Spurs Growth
    • Increasing Adoption of Wearable Health Technology Drives Demand for Artificial Pancreas Devices
    • Innovation in Biocompatible Materials and Sensors Generates Opportunities for Enhanced Device Durability
    • Development of Dual-Hormone Systems Throws the Spotlight on Next-Generation Solutions
    • Rising Incidence of Type 1 Diabetes Among Youth Fuels Market Growth
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Artificial Pancreas Device Systems by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 2: World 7-Year Perspective for Artificial Pancreas Device Systems by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2024 & 2030
    • TABLE 3: World Artificial Pancreas Device Systems Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Threshold Suspended Device Systems by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 5: World 7-Year Perspective for Threshold Suspended Device Systems by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Control-to-Target (CTT) Systems by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 7: World 7-Year Perspective for Control-to-Target (CTT) Systems by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Control-to-Range (CTR) Systems by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 9: World 7-Year Perspective for Control-to-Range (CTR) Systems by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Artificial Pancreas Device Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 10: USA Recent Past, Current & Future Analysis for Artificial Pancreas Device Systems by Device - Threshold Suspended Device Systems, Control-to-Target (CTT) Systems and Control-to-Range (CTR) Systems - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 11: USA 7-Year Perspective for Artificial Pancreas Device Systems by Device - Percentage Breakdown of Value Sales for Threshold Suspended Device Systems, Control-to-Target (CTT) Systems and Control-to-Range (CTR) Systems for the Years 2024 & 2030
  • CANADA
    • TABLE 12: Canada Recent Past, Current & Future Analysis for Artificial Pancreas Device Systems by Device - Threshold Suspended Device Systems, Control-to-Target (CTT) Systems and Control-to-Range (CTR) Systems - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 13: Canada 7-Year Perspective for Artificial Pancreas Device Systems by Device - Percentage Breakdown of Value Sales for Threshold Suspended Device Systems, Control-to-Target (CTT) Systems and Control-to-Range (CTR) Systems for the Years 2024 & 2030
  • JAPAN
    • Artificial Pancreas Device Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 14: Japan Recent Past, Current & Future Analysis for Artificial Pancreas Device Systems by Device - Threshold Suspended Device Systems, Control-to-Target (CTT) Systems and Control-to-Range (CTR) Systems - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 15: Japan 7-Year Perspective for Artificial Pancreas Device Systems by Device - Percentage Breakdown of Value Sales for Threshold Suspended Device Systems, Control-to-Target (CTT) Systems and Control-to-Range (CTR) Systems for the Years 2024 & 2030
  • CHINA
    • Artificial Pancreas Device Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 16: China Recent Past, Current & Future Analysis for Artificial Pancreas Device Systems by Device - Threshold Suspended Device Systems, Control-to-Target (CTT) Systems and Control-to-Range (CTR) Systems - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 17: China 7-Year Perspective for Artificial Pancreas Device Systems by Device - Percentage Breakdown of Value Sales for Threshold Suspended Device Systems, Control-to-Target (CTT) Systems and Control-to-Range (CTR) Systems for the Years 2024 & 2030
  • EUROPE
    • Artificial Pancreas Device Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 18: Europe Recent Past, Current & Future Analysis for Artificial Pancreas Device Systems by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 19: Europe 7-Year Perspective for Artificial Pancreas Device Systems by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2024 & 2030
    • TABLE 20: Europe Recent Past, Current & Future Analysis for Artificial Pancreas Device Systems by Device - Threshold Suspended Device Systems, Control-to-Target (CTT) Systems and Control-to-Range (CTR) Systems - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 21: Europe 7-Year Perspective for Artificial Pancreas Device Systems by Device - Percentage Breakdown of Value Sales for Threshold Suspended Device Systems, Control-to-Target (CTT) Systems and Control-to-Range (CTR) Systems for the Years 2024 & 2030
  • FRANCE
    • Artificial Pancreas Device Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 22: France Recent Past, Current & Future Analysis for Artificial Pancreas Device Systems by Device - Threshold Suspended Device Systems, Control-to-Target (CTT) Systems and Control-to-Range (CTR) Systems - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 23: France 7-Year Perspective for Artificial Pancreas Device Systems by Device - Percentage Breakdown of Value Sales for Threshold Suspended Device Systems, Control-to-Target (CTT) Systems and Control-to-Range (CTR) Systems for the Years 2024 & 2030
  • GERMANY
    • Artificial Pancreas Device Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 24: Germany Recent Past, Current & Future Analysis for Artificial Pancreas Device Systems by Device - Threshold Suspended Device Systems, Control-to-Target (CTT) Systems and Control-to-Range (CTR) Systems - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 25: Germany 7-Year Perspective for Artificial Pancreas Device Systems by Device - Percentage Breakdown of Value Sales for Threshold Suspended Device Systems, Control-to-Target (CTT) Systems and Control-to-Range (CTR) Systems for the Years 2024 & 2030
  • ITALY
    • TABLE 26: Italy Recent Past, Current & Future Analysis for Artificial Pancreas Device Systems by Device - Threshold Suspended Device Systems, Control-to-Target (CTT) Systems and Control-to-Range (CTR) Systems - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Italy 7-Year Perspective for Artificial Pancreas Device Systems by Device - Percentage Breakdown of Value Sales for Threshold Suspended Device Systems, Control-to-Target (CTT) Systems and Control-to-Range (CTR) Systems for the Years 2024 & 2030
  • UNITED KINGDOM
    • Artificial Pancreas Device Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 28: UK Recent Past, Current & Future Analysis for Artificial Pancreas Device Systems by Device - Threshold Suspended Device Systems, Control-to-Target (CTT) Systems and Control-to-Range (CTR) Systems - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 29: UK 7-Year Perspective for Artificial Pancreas Device Systems by Device - Percentage Breakdown of Value Sales for Threshold Suspended Device Systems, Control-to-Target (CTT) Systems and Control-to-Range (CTR) Systems for the Years 2024 & 2030
  • REST OF EUROPE
    • TABLE 30: Rest of Europe Recent Past, Current & Future Analysis for Artificial Pancreas Device Systems by Device - Threshold Suspended Device Systems, Control-to-Target (CTT) Systems and Control-to-Range (CTR) Systems - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 31: Rest of Europe 7-Year Perspective for Artificial Pancreas Device Systems by Device - Percentage Breakdown of Value Sales for Threshold Suspended Device Systems, Control-to-Target (CTT) Systems and Control-to-Range (CTR) Systems for the Years 2024 & 2030
  • ASIA-PACIFIC
    • Artificial Pancreas Device Systems Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 32: Asia-Pacific Recent Past, Current & Future Analysis for Artificial Pancreas Device Systems by Device - Threshold Suspended Device Systems, Control-to-Target (CTT) Systems and Control-to-Range (CTR) Systems - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Asia-Pacific 7-Year Perspective for Artificial Pancreas Device Systems by Device - Percentage Breakdown of Value Sales for Threshold Suspended Device Systems, Control-to-Target (CTT) Systems and Control-to-Range (CTR) Systems for the Years 2024 & 2030
  • REST OF WORLD
    • TABLE 34: Rest of World Recent Past, Current & Future Analysis for Artificial Pancreas Device Systems by Device - Threshold Suspended Device Systems, Control-to-Target (CTT) Systems and Control-to-Range (CTR) Systems - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 35: Rest of World 7-Year Perspective for Artificial Pancreas Device Systems by Device - Percentage Breakdown of Value Sales for Threshold Suspended Device Systems, Control-to-Target (CTT) Systems and Control-to-Range (CTR) Systems for the Years 2024 & 2030

IV. COMPETITION